Literature DB >> 8862349

Polymyositis as a manifestation of chronic graft-versus-host disease.

P Parker1, N J Chao, J Ben-Ezra, N Slatkin, H Openshaw, J C Niland, C A Linker, B S Greffe, A Kashyap, A Molina, A Nademanee, M R O'Donnell, I Planas, K Sheibani, E P Smith, D S Snyder, R Spielberger, A S Stein, D E Stepan, K G Blume, S J Forman.   

Abstract

A syndrome indistinguishable from idiopathic polymyositis occurred in 11 patients as a manifestation of chronic GVHD. All patients had elevation of creatine phosphokinase (CPK). Immunohistology demonstrated the effector cells in the muscle infiltrates as cytotoxic T cells, a finding similar to idiopathic polymyositis. Polymyositis is a rarely reported complication of chronic graft-versus-host disease (GVHD) with only 8 cases described in the literature. We encountered this syndrome in a small but significant percentage of our patients with chronic GVHD. Polymyositis associated with chronic GVHD does not affect the overall prognosis for the patient. Moreover, polymyositis can be the only manifestation of chronic GVHD. Awareness of this complication is important because it can be confused with other causes of muscle weakness after bone marrow transplantation. Finally, prompt initiation of corticosteroid therapy results in a rapid improvement of the associated symptoms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862349     DOI: 10.1097/00005792-199609000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  6 in total

1.  MR findings in patients with disabling musculocutaneous chronic graft-versus-host disease.

Authors:  M Horger; A Boss; W Bethge; C Faul; G Fierlbeck; A Bornemann; C D Claussen; W Vogel
Journal:  Skeletal Radiol       Date:  2008-07-12       Impact factor: 2.199

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Authors:  Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

Review 3.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

4.  IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis.

Authors:  I Colombo; M E Fruguglietti; L Napoli; M Sciacco; E Tagliaferri; A Della Volpe; V Crugnola; N Bresolin; M Moggio; A Prelle
Journal:  Neurol Res Int       Date:  2010-07-19

5.  Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.

Authors:  Sooraj John; Scott J Antonia; Trevor A Rose; Robert P Seifert; Barbara A Centeno; Aaron S Wagner; Ben C Creelan
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

Review 6.  Foreign cells in polymyositis: could stem cell transplantation and pregnancy-derived chimerism lead to the same disease?

Authors:  Anne M Stevens
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.686

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.